Journal: NPJ Vaccines

Article Title: SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN ® , induces robust humoral and cellular immunity in mice and non-human primates

doi: 10.1038/s41541-022-00528-3

Figure Lengend Snippet: a BALB/c ( n = 20 each group) and C57BL/6 mice ( n = 12 each group) were i.m. injected with 0.05 (light pink), 0.5 (pink) or 3 µg (purple) COReNAPCIN ® at day 0 and day 21. Animals in the control group received PBS injection (gray). b – d Sera were collected before and at different days post prime and tested for SARS-CoV-2 Spike-specific total IgG by ELISA. In ( d ), the anti-S IgG specific binding antibody endpoint titer of five different time points in male and female BALB/c is compared. e – g The sera of day 40 post prime were assessed for anti-RBD IgG binding antibody using ELISA ( e ), for neutralizing capacity against pseudotype SARS-CoV-2 using pVNT ( f ) and for ACE2 binding inhibition ability using sVNT ( g ). Each data point is shown, the height of each bar represents the geometric mean. All statistical analyses were performed using one-way ANOVA followed by multiple comparisons Dunn’s post-hoc test. A p value less than 0.05 (*** P < 0.001, **** P < 0.0001) was assumed to be statistically significant.

Article Snippet: We used sVNT (ACE2 inhibition test) ELISA (Pishtaz Teb) (with a detection limit of 40 μg/ml), for measuring the SARS-COV-2 neutralizing ability of serum samples of mice and rhesus macaques collected 40 days post-prime.

Techniques: Injection, Control, Enzyme-linked Immunosorbent Assay, Binding Assay, Inhibition

Journal: NPJ Vaccines

Article Title: SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN ® , induces robust humoral and cellular immunity in mice and non-human primates

doi: 10.1038/s41541-022-00528-3

Figure Lengend Snippet: a Rhesus macaques ( n = 2 each group) were immunized with either 30 µg (pink) or 50 µg (purple) COReNAPCIN ® at days 0 and 28 and were challenged with 2 × 10 8 PFU of SARS-CoV-2, 21 days after the boost injection. Animals in the control group were administrated with PBS (gray). b – f Serum samples were subjected for evaluating the COReNAPCIN ® induced humoral immune responses. The black arrows under the x-axis represent vaccination days while the red one denotes the challenge day. The titer of anti-Spike ( b ) and anti-RBD ( d ) specific IgG binding antibody in sera before prime and eight indicated time points post prime were determined by ELISA. The neutralizing capacity were assessed in the sera of day 14 post boost by cVNT ( c ), and in the sera of indicated different time points by sVNT ( d ) and pVNT ( f ). g – i PBMCs isolated 21 days post-boost injection, were subjected for assessing the COReNAPCIN ® induced cellular immune response. Using an ELISpot assay ( g , h ), after 24 h stimulation with SARS-CoV-2 peptide pool (S1 and S2), the frequency of IFN-γ producing cells per 10 6 splenocytes were quantified ( h ). In ( g ), the representative images of ELISpot wells, columns from left to right are: responses of PBMCs to S1 and S2 SARS-CoV-2 peptide pool (as duplicate), DMSO (a negative control), and Anti CD3 (an unspecific positive control). Each row represents an individual rhesus macaque. An ELISA assay ( i ) was used to assess the IFN-γ (square shape symbol, □) and IL-4 (circle shape symbol, ●) cytokine level in the cell culture supernatants following 8 h stimulation with SARS-CoV-2 peptide pool. In bar plots, each data point is shown and the height of each bar represents the mean.

Article Snippet: We used sVNT (ACE2 inhibition test) ELISA (Pishtaz Teb) (with a detection limit of 40 μg/ml), for measuring the SARS-COV-2 neutralizing ability of serum samples of mice and rhesus macaques collected 40 days post-prime.

Techniques: Injection, Control, Binding Assay, Enzyme-linked Immunosorbent Assay, Isolation, Enzyme-linked Immunospot, Negative Control, Positive Control, Cell Culture

Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: (A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) SARS-CoV-2 S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Microarray, Neutralization, MANN-WHITNEY, Inhibition, Release Assay

Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: ( A ) Anti-SARS-CoV-2 N, ( B ) RBD- ( C ) and full-spike IgG measured in the serum of BNT162b2 vaccinated HCW and elderly persons six months after the first vaccination. ( D ) Neutralizing capacity was measured by sVNT and ( E ) serum neutralization against Alpha (B.1.1.7) VOC detected by pNT in vaccinated HCW and elderly persons six months after the first vaccination. ( F ) Binding capacity of serum IgG against six different RBDs of SARS-CoV-2 variants carrying the indicated mutations in HCW and elderly, measured by ELISA. Dotted lines indicate the manufacturer’s threshold values: for anti-N, anti-RBD, and anti-full spike IgG ≥1 S/Co, for sVNT >30%, and the lower limit of detection (1:10 dilution) for pNT. Lines indicate the median and interquartile range except for pNT, where the geometric mean and 95% confidence interval are shown. P values were calculated by the non-parametric Mann Whitney U test or Kruskal-Wallis test with Dunn’s multiple comparisons test. S/Co: signal-to-cutoff, N: nucleocapsid protein, RBD: receptor-binding domain, sVNT: surrogate virus neutralization test, ACE2: angiotensin-converting enzyme 2, ID50: 50% inhibition dilution.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Neutralization, Binding Assay, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY, Inhibition